# Multi-country Viral Hepatitis COMmunity Screening, Vaccination, and Care (VH-COMSAVAC): Project outline

Angelo Maria Pezzullo, Camila A Picchio, Leonardo Villani, Domenico Pascucci, Roberta Pastorino, Matteo Di Pumpo, Abdelrahman Taha, Lena Van Selm, Delfina Boudou, Davide Fortin, Giorgos Kalamitsis, Massimo Colombo, Giuseppe Colucci, Pietro Lampertico, Antonio G. De Belvis, Carlo La Vecchia, Stefania Boccia, Jeffrey V. Lazarus



## **Background & Objective**

- Chronic viral hepatitis infection caused by the hepatitis B and C viruses (HBV and HCV) is a major public health challenge. In high-income countries, HBV and HCV infections are more prevalent among marginalized communities, such as migrants and refugees.
- In line with "Europe's Beating Cancer"
  plan, the EU4Health program has funded
  Multi-country Viral Hepatitis COMmunity
  Screening, Vaccination, and Care (VHCOMSAVAC) that seeks to leverage
  established partner networks offering
  community-based HBV and HCV
  screening and appropriately link people to
  specialist care and vaccination in order to
  reduce the liver cancer burden caused by
  HBV and HCV infections in the European
  Union (EU).




Figure 1. Viral hepatitis cascade of care and continuum of services adapted from WHO guidelines on HBV and HCV testing

### **Methods**

#### The project will:

- take place in three EU member countries: Greece, Italy and Spain.
- employ effective and established community-based care models for hardto-reach, marginalized populations, specifically migrants and refugees
- adapt and scale up early HBV and HCV screening using simple and innovative diagnostic tools, decentralized vaccination against HBV and linkage-to-care with hospitals specializing in the treatment of viral hepatitis.

## **Expected results**

- Migrant and marginalised populations included in the project will benefit by:
  - knowing their HBV and HCV status,
  - being offered the first-dose of the HBV vaccine *in situ*, if appropriate
  - being provided an expedited referral to specialist care for treatment initiation and management, if needed.
- Process, outcome, and cost indicators
   (Figure 1) will be collected. An economic
   assessment of the impact and value of
   these interventions on liver cancer burden
   to inform future policies and guidelines.
- The results of the community-based screening program will provide evidence to inform guidelines for tailored, personcentred models of viral hepatitis care.





## Conclusion

 The results obtained from the interventions will provide clinical and costeffectiveness data to contribute to the development of a roadmap to reducing the liver cancer burden associated with HBV and HCV infections in the EU.















